1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 15
1.3.1 MARKETS COVERED 15
1.3.2 YEARS CONSIDERED IN THE REPORT 16
1.4 CURRENCY 17
1.5 LIMITATION 17
1.6 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 30
4.1 GLOBAL CLINICAL TRIALS IMAGING MARKET OVERVIEW 30
4.2 LIFE CYCLE ANALYSIS, BY REGION (2015-2020) 32

5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.2 MARKET SEGMENTATION 34
5.2.1 BY PRODUCT 34
5.2.2 BY MODALITY 35
5.2.3 BY END USER 35
5.3 MARKET DYNAMICS 36
5.3.1 DRIVERS 37
5.3.1.1 Increase in R&D spending 37
5.3.1.2 Growth in the pharmaceutical and biotechnology industries 38
5.3.1.3 Increasing number of CROs 38
5.3.2 RESTRAINTS 39
5.3.2.1 High implementation cost of imaging systems 39
?
5.3.3 OPPORTUNITIES 40
5.3.3.1 Emerging economies 40
5.3.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, & radiopharmaceuticals 41
5.3.4 CHALLENGES 41
5.3.4.1 High cost of clinical trials 41
5.3.4.2 High cost of PET 41
5.3.5 TRENDS 42
5.3.5.1 Rising demand for multimodality imaging technology in clinical trials 42

6 CLINICAL TRIALS IMAGING MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 SERVICES 46
6.2.1 OPERATIONAL IMAGING 48
6.2.2 READ ANALYSIS 50
6.2.3 SYSTEM AND TECHNICAL SUPPORT 52
6.2.4 TRIAL DESIGN CONSULTING 53
6.3 SOFTWARE 55

7 CLINICAL TRIALS IMAGING MARKET, BY MODALITY 57
7.1 INTRODUCTION 58
7.2 COMPUTED TOMOGRAPHY 60
7.3 MAGNETIC RESONANCE IMAGING 62
7.4 ULTRASOUND 64
7.5 POSITRON EMISSION TOMOGRAPHY 66
7.6 X-RAY 68
7.7 ECHOCARDIOGRAPHY 69
7.8 OTHER MODALITIES 71

8 CLINICAL TRIALS IMAGING MARKET, BY END USER 73
8.1 INTRODUCTION 74
8.2 PHARMACEUTICAL COMPANIES 76
8.3 BIOTECHNOLOGY COMPANIES 78
8.4 MEDICAL DEVICE MANUFACTURERS 80
8.5 CONTRACT RESEARCH ORGANIZATIONS 82
8.6 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 84
8.7 OTHER END USERS 86
?

9 GEOGRAPHIC ANALYSIS 88
9.1 INTRODUCTION 89
9.2 NORTH AMERICA 91
9.3 EUROPE 98
9.4 ASIA 103
9.5 REST OF THE WORLD (ROW) 109

10 COMPETITIVE LANDSCAPE 114
10.1 INTRODUCTION 114
10.2 STRATEGIC OVERVIEW 114
10.3 LEADING PLAYERS IN THE CLINICAL TRIALS IMAGING MARKET 115
10.4 COMPETITIVE SITUATION AND TRENDS 116
10.4.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 117
10.4.2 ACQUISITIONS 118
10.4.3 NEW PRODUCT AND SERVICE LAUNCHES & PRODUCT UPGRADES 119
10.4.4 EXPANSIONS 120
10.4.5 OTHER DEVELOPMENTS 121

11 COMPANY PROFILES 122
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 INTRODUCTION 122
11.2 BIOCLINICA, INC. 123
11.3 PAREXEL INTERNATIONAL CORPORATION 125
11.4 ICON PUBLIC LIMITED COMPANY 128
11.5 BIOMEDICAL SYSTEMS CORPORATION 131
11.6 VIRTUALSCOPICS, INC. 133
11.7 CARDIOVASCULAR IMAGING TECHNOLOGIES, LLC 135
11.8 INTRINSIC IMAGING LLC 136
11.9 IXICO PLC 137
11.10 RADIANT SAGE LLC 139
11.11 WORLDCARE CLINICAL, LLC 140
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

12 APPENDIX 141
12.1 INSIGHTS OF INDUSTRY EXPERTS 141
12.2 DISCUSSION GUIDE 142
12.3 OTHER DEVELOPMENTS 144
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146
12.5 AVAILABLE CUSTOMIZATIONS 147
12.6 RELATED REPORTS 148